| Literature DB >> 30338246 |
Vasiliki Chondrou1, Katerina Trochoutsou1, Andreas Panayides1, Maria Efthimiou1, Georgia Stephanou1, Nikos A Demopoulos1.
Abstract
BACKGROUND: Doxorubicin is a widely used anticancer drug due to its broad spectrum of antitumor activity. Various mechanisms have been proposed for its cytostatic activity, including DNA intercalation, topoisomerase II inhibition, generation of free radicals and apoptosis. The present study aims to further clarify the cytostatic activity of doxorubicin by its specific effect on (a) DNA damage, (b) micronucleation and (c) apoptosis, using a combination of different methods and cell systems such as human lymphocytes and HL-60 human leukemic cells. DNA lesions were analyzed by the alkaline comet assay in combination with formamidopyrimidine (Fpg) and human 8-oxoguanine (hOGG1) repair enzymes. Micronucleation was investigated by the Cytokinesis-Block Micronucleus assay (CBMN) in combination with Fluorescence In Situ Hybridization analysis. Impairment on mitotic apparatus was investigated by double immunofluorescence of β- and γ-tubulin. Apoptotic cell frequency was determined by the CBMN cytome assay. Complementary to the above, caspase-3 level was investigated by Western blot.Entities:
Keywords: Apoptosis-caspase-3; Doxorubicin; Fpg and hOGG1 comet assay; Micronucleation; Mitotic spindle disturbance
Year: 2018 PMID: 30338246 PMCID: PMC6180587 DOI: 10.1186/s40709-018-0089-z
Source DB: PubMed Journal: J Biol Res (Thessalon) ISSN: 1790-045X Impact factor: 1.889
Fig. 1Genetic endpoints studied in different cell types and methodology followed
Fig. 2% DNA in tail in HL-60 comets after treatment with various concentrations of doxorubicin. H2O2 (100 μM) was used as positive control. DNA was stained with ethidium bromide. *p ≤ 0.05 in comparison with control (one-way ANOVA). Bars represent standard error
Fig. 3% DNA in tail in HL-60 comets after treatment with doxorubicin and incubation of nucleoids with Fpg or hOGG1 endonuclease. Data represent values generated by Fpg (a1) and hOGG1 (a2) incubation, that were calculated by subtracting the value of DNA damage caused in the HL-60 cells that were not treated with the respective enzyme from the DNA damage caused in cells incubated with the enzymes. Subtracted values are pointed out in light grey area marked ‘‘Fpg sites’’ and “hOGG1 sites”. b HL-60 comets, no doxorubicin treatment/no endonuclease incubation (b); no doxorubicin treatment/Fpg endonuclease incubation (b); no doxorubicin treatment/hOGG1 endonuclease incubation (b); doxorubicin treatment at 0.5 μg ml−1/no endonuclease incubation (b); doxorubicin treatment at 0.5 μg ml−1/Fpg endonuclease incubation (b); doxorubicin treatment at 0.5 μg ml−1/hOGG1 endonuclease incubation (b); doxorubicin treatment at 2.0 μg ml−1/no endonuclease incubation (b); doxorubicin treatment at 2.0 μg ml−1/Fpg endonuclease incubation (b) and doxorubicin treatment at 2.0 μg ml−1 /hOGG1 endonuclease incubation (b). DNA was stained with ethidium bromide. * p ≤ 0.05 in comparison with untreated cells (one-way ANOVA). Bars represent standard error
Fig. 4a Micronucleus frequency in human lymphocytes treated with doxorubicin. a Cytokinesis Block Micronucleus Index (CBPI) in human lymphocytes treated with doxorubicin. b FISH analysis with pancentromeric probe. c Lymphocytes with C−MN (c) and C+MN (c). (C−MN: micronucleus without centromeric signal, C+MN: micronucleus exerting centromeric signal. * p ≤ 0.05 in comparison with control (G-test). Vincristine sulfate was used as a positive control. The values represent the average of the two donors. Bars represent standard error
Induction of apoptosis and micronucleation in HL-60 cells after treatment with doxorubicin
| Doxorubicin (μg ml−1) | Induction of apoptosis | Total cells | Micronucleus Induction | ||||
|---|---|---|---|---|---|---|---|
| Total cells | Live cells (%) | Apoptotic cells (%) | Cells with MN (%) | CBPI | Cytotoxicity (%) | ||
| 0 | 9262 | 8507 | 748 | 5122 | 55 | 1.55 ± 0.07 | – |
| 0.5 | 10,614 | 4260 | 6220 | 2329 | 47 | 1.22 ± 0.03 | 60.01 ± 3.35 |
| 2 | 10,673 | 1417 | 8587 | 483 | 8 | 1.28 ± 0.07 | 50.61 ± 9.77 |
MN micronucleus, CPBI Cytokinesis Block Proliferation Index, SE standard error
* p ≤ 0.0001 in comparison with control (G-test)
Fig. 5a Western blots and b densitometric quantification, showing the caspase-3 level in HL-60 cells after treatment with doxorubicin. * p ≤ 0.05 in comparison with control (G-test). Bars represent standard error
Mitotic figure distribution and the effect on the M.I. in C2C12 cells treated with doxorubicin
| Chemical compound (μg ml−1) | Total mitotic cells | Prophases (%) | Metaphases (%) | Ana-telophases (%) | Total abnormal mitotic cells (%) | Total abnormal metaphases (%) | Mitotic Index (%) |
|---|---|---|---|---|---|---|---|
| 0 | 1436 | 24 | 474 | 938 | 152 | 149 | 5.86 |
| DOX 0.05 | 658 | 5 | 159 | 494 | 477 | 112 | 1.34 |
| DEM 0.005 | 650 | 9 | 425 | 216 | 409 | 385 | 2.14 |
DOX doxorubicin, DEM demecolcine was used as positive control, M.I. Mitotic Index, SE standard error
* p ≤ 0.0001 in comparison with control (G-test)
Fig. 6a Frequency of abnormal C2C12 metaphases in relation to γ-tubulin signals and chromosome orientation. b Distinct types of metaphase cells: normal metaphase (b); monopolar metaphase (b); tripolar metaphase (b); multipolar metaphase (b); and bipolar non-congressed metaphases (b). * p ≤ 0.05 in comparison with control (G-test). Demecolcine was used as positive control. Bars represent standard error